Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection.
Brucella abortus, a facultative intracellular pathogen, is of tremendous zoonotic importance because of its ability to induce spontaneous abortion in cattle and other livestock. It is also known to cause persistent undulant fever, endocarditis, arthritis, osteomyelitis and meningitis in humans. The available vaccines against this dreadful infection suffer from limitations like short-term immunity, increased risk of hypersensitivity and low prophylactic index in the recipients. In the present study, we have demonstrated that liposomal form of a recombinant ribosomal L7/L12 protein, a B-T cell antigen of B. abortus, activates strong immune response in the host. In contrast, free antigen generates moderate immune response in the immunised animals. The liposomisation of rL7/L12 protein causes tremendous increase in cell-mediated immune response in terms of delayed type hypersensitivity, T-cell proliferation and up-regulation in type I cytokine expression, etc. Moreover, the liposome encapsulated antigen elicited stronger humoral immune response as compared to standard vaccine (S-19) or IFA-L7/L12 combination in the immunised animals. The effectiveness of liposome-based vaccine was also substantiated by better systemic clearance of bacterial load after challenging the animals with B. abortus 544 pathogen. The results of the present study suggest the potential of liposome-based rL7/L12 antigen as prospective and efficient candidate vaccine capable of eliciting both cell mediated as well as humoral immune responses against experimental murine brucellosis.
Mallick
A I
AI
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh-202002, India.
Singha
H
H
Chaudhuri
P
P
Nadeem
Ahmad
A
Khan
Shadab Ahmad
SA
Dar
Khurshid Ahmad
KA
Owais
M
M
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002004:Brucella Vaccine / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D002003:Brucella abortus / Q000276:immunology* / Q000472:pathogenicity; D002006:Brucellosis / Q000382:microbiology / Q000517:prevention & control*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D007114:Immunization; D007371:Interferon-gamma / Q000096:biosynthesis; D008081:Liposomes / Q000008:administration & dosage*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D012269:Ribosomal Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology
D000907:Antibodies, Bacterial; D002004:Brucella Vaccine; D008081:Liposomes; D011994:Recombinant Proteins; D012269:Ribosomal Proteins; C016700:ribosomal protein L7-L12; D007371:Interferon-gamma